DrugPatentWatch Database Preview
Drugs in Development Information for Deoxythymidine
» See Plans and Pricing
What is the development status for investigational drug Deoxythymidine?
Deoxythymidine is an investigational drug.
There have been 9 clinical trials for Deoxythymidine.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Infection. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), Modis Therapeutics, Inc., and Bristol-Myers Squibb.
There are two US patents protecting this investigational drug and forty-five international patents.
Summary for Deoxythymidine
| US Patents | 2,735 |
| International Patents | 45,588 |
| US Patent Applications | 3,979 |
| WIPO Patent Applications | 2,800 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2020-12-01) |
| Vendors | 84 |
Recent Clinical Trials for Deoxythymidine
| Title | Sponsor | Phase |
|---|---|---|
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency | Zogenix, Inc. | Phase 3 |
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency | Modis Therapeutics, Inc. | Phase 3 |
| An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 | Modis Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for Deoxythymidine
Top disease conditions for Deoxythymidine
Top clinical trial sponsors for Deoxythymidine
US Patents for Deoxythymidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Deoxythymidine | Start Trial | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (Brussels, BY) KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (Leuven, BE) | Start Trial |
| Deoxythymidine | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| Deoxythymidine | Start Trial | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | Janssen Biotech, Inc. (Horsham, PA) | Start Trial |
| Deoxythymidine | Start Trial | Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom | MERIAL, INC. (Duluth, GA) | Start Trial |
| Deoxythymidine | Start Trial | Alphaviral vectors and cell lines for producing recombinant proteins | 3P BIOPHARMACEUTICALS, S.L. (Noain (Navarra), ES) | Start Trial |
| Deoxythymidine | Start Trial | Method for high throughput screening of nucleic acids | Complete Genomics, Inc. (San Jose, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Deoxythymidine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Deoxythymidine | Brazil | BR112016029632 | 2034-06-17 | Start Trial |
| Deoxythymidine | Canada | CA2951349 | 2034-06-17 | Start Trial |
| Deoxythymidine | China | CN106559992 | 2034-06-17 | Start Trial |
| Deoxythymidine | European Patent Office | EP3157924 | 2034-06-17 | Start Trial |
| Deoxythymidine | United Kingdom | GB201410817 | 2034-06-17 | Start Trial |
| Deoxythymidine | Japan | JP2017518385 | 2034-06-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
